Rubius Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2016 to 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Rubius Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to 2022.
  • Rubius Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2022 was -$20.1M, a 63.4% increase year-over-year.
  • Rubius Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2022 was -$180M, a 8.59% increase year-over-year.
  • Rubius Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$180M, a 8.59% increase from 2021.
  • Rubius Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$197M, a 17.2% decline from 2020.
  • Rubius Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$168M, a 2.61% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$180M +$16.9M +8.59% Jan 1, 2022 Dec 31, 2022 10-K 2023-02-27
2021 -$197M -$28.8M -17.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-27
2020 -$168M -$4.27M -2.61% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$163M -$74.3M -83.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$89.2M -$45.3M -103% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-23
2017 -$43.8M -$32.8M -298% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$11M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.